Barriers and facilitators for assessment and treatment of hepatitis C virus infection in the opioid substitution treatment setting: Insights from the ETHOS study

Journal of Viral Hepatitis

Volumn 21, Issue 8, 2014, Pages 560-567

  Treloar, C ^a   Rance, J ^a   Dore, G J ^b   Grebely, J ^b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

hepatitis C; opiate substitution treatment; qualitative research; treatment

Indexed keywords

INTERFERON; OPIATE;

ADULT; ARTICLE; CONVERSATION; DECISION MAKING; DRUG TOLERABILITY; FEMALE; FRIEND; HEALTH PRACTITIONER; HEPATITIS C; HUMAN; INTERPERSONAL COMMUNICATION; INTERVIEW; LIVER INJURY; MAJOR CLINICAL STUDY; MALE; MOTIVATION; OPIATE SUBSTITUTION TREATMENT; PATIENT ATTITUDE; PERCEPTION; PRIORITY JOURNAL; QUALITATIVE RESEARCH; SOCIAL SECURITY; SYMPTOM; AUSTRALIA; COHORT ANALYSIS; HEPATITIS C, CHRONIC; MIDDLE AGED; PROSPECTIVE STUDY;

ADULT; AUSTRALIA; COHORT STUDIES; FEMALE; HEPATITIS C, CHRONIC; HUMANS; MALE; MIDDLE AGED; OPIATE SUBSTITUTION TREATMENT; PATIENT ACCEPTANCE OF HEALTH CARE; PROSPECTIVE STUDIES;

EID: 84903814910     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12183     Document Type: Article

References (41)

1. Grebely J, Dore G,. What is killing people with hepatitis C virus infection? Semin Liver Dis 2012; 31 (4): 331-339.
2. van der Meer A, Veldt B, Feld J, et al,. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012; 308 (24): 2584-2593.
3. Lettmeier B, Muhlberger N, Schwarzer R, et al,. Market uptake of new antiviral drugs for the treatment of hepatitis C. J Hepatol 2008; 49 (4): 528-536.
4. Volk M, Tocco R, Saini S, Lok A,. Public health impact of antiviral therapy for hepatitis C in the United States. Hepatology 2010; 50 (6): 1750-1755.
5. Butt A, Justice A, Skanderson M, Rigsby M, Good C, Kwoh C,. Rate and predictors of treatment prescription for hepatitis C. Gut 2007; 56 (3): 385-389. (Pubitemid 46579770)
6. Grebely J, Raffa J, Lai C, et al,. Low uptake of treatment for hepatitis C virus infection in a large community-based study of inner city residents. J Viral Hepat 2009; 16: 352-358.
7. Mehta S, Genberg BL, Astemborsk J, et al,. Limited uptake of hepatitis C treatment among injection drug users. J Community Health 2008; 33: 126-133.
8. Iversen J, Grebely J, Topp L, Wand H, Dore GJ, Maher L,. Uptake of hepatitis C treatment among people who inject drugs attending Needle and Syringe Programs in Australia, 1999-2011. J Viral Hepat. 2013 doi: 10.1111/jvh.12129.
9. Grebely J, Tyndall M,. Management of HCV and HIV infections among people who inject drugs. Curr Opin HIV AIDS 2011; 6 (6): 501-507.
10. Harris M, Jolly E, Martin A, Wells H, Rhodes T,. Barriers and Facilitators to Hepatitis C Treatment for People Who Inject Drugs: A Qualitative Study. Copenhagen: World Health Organisation, 2012.
11. Morrill JA, Shrestha M, Grant RW,. Barriers to the treatment of hepatitis C: patient, provider and system factors. J Gen Intern Med 2005; 20: 754-758. (Pubitemid 41141009)
12. McGowan C, Fried M,. Barriers to hepatitis C treatment. Liver Int 2012; 32 (Suppl. 1): 151-156
13. Bruggmann P, Litwin A,. Models of care for the management of HCV among people who use drugs: one size does not fit all. Clin Infect Dis 2013; 57 (Suppl. 2): S56-S61.
14. Dimova R, Zeremski M, Jacobson I, Hagan H, Des Jarlais D, Talal A,. Determinants of hepatitis C virus treatment completion and efficacy in drug users assessed by meta-analysis. Clin Infect Dis 2013; 56 (6): 806-816.
15. Hellard M, Sacks-Davis R, Gold J,. Hepatitis C treatment for injecting drug users: a review of the available evidence. Clin Infect Dis 2009; 49: 561-573.
16. Krook A, Stokka D, Heger B, Nygaard E,. Hepatitis C treatment of opioid dependants receiving maintenance treatment: results of a Norwegian pilot study. Eur Addict Res 2007; 13 (4): 216-221. (Pubitemid 47414339)
17. Harris KJ, Arnsten J, Litwin A,. Successful integration of hepatitis C evaluation and treatment services with methadone maintenance. J Addict Med 2010; 4 (1): 20-26.
18. Litwin A, Harris KJ, Nahvi S, et al,. Successful treatment of chronic hepatitis C with pegylated interferon in combination with ribavirin in a methadone maintenance treatment program. J Subst Abuse Treat 2009; 37: 32-40.
19. Rance J, Newland J, Hopwood M, Treloar C,. The politics of place(ment): problematizing the provision of hepatitis C treatment within opiate substation clinics. Soc Sci Med 2012; 74 (2): 245-253.
20. Treloar C, Newland J, Rance J, Hopwood M,. Uptake and delivery of hepatitis C treatment in opiate substitution treatment: perceptions of clients and health professionals. J Viral Hepat 2010; 17: 839-844.
21. Alavi M, Grebely J, Micallef M, et al,. Assessment and treatment of hepatitis C virus infection among people who inject drugs in the opiate substitution setting: the ETHOS study. Clin Infect Dis 2013; 57 (Suppl. 2): S62-S69.
22. Braun V, Clarke V,. Using thematic analysis in psychology. Qual Res Psychol 2006; 3 (2): 77-101.
23. Swan D, Long J, Carr O, et al,. Barriers to and facilitators of hepatitis C testing, management and treatment among current and former injecting drug users: a qualitative exploration. AIDS Patient Care and STDs 2010; 24 (12): 753-762.
24. Grebely J, Bryant J, Hull P, et al,. Factors associated with specialist assessment and treatment for hepatitis C virus infection in New South Wales, Australia. J Viral Hepat 2011; 18: 104-116.
25. Doab A, Treloar C, Dore G,. Hepatitis C treatment knowledge, attitudes and barriers among current injecting drug users in Australia. Clin Infect Dis 2005; 40 (Suppl. 5): S313-S320. (Pubitemid 40490217)
26. Bova C, Ogawa L, Sullivan-Bolyai S,. Hepatitis C treatment experiences and decision making among patients living with HIV infection. J Assoc Nurses AIDS Care 2010; 21 (1): 63-74.
27. Fraser S, Valentine k,. Substance and Substitution: Methadone Subjects in Liberal Societies. Basingstoke: Palgrave Macmillan, 2008.
28. Treloar C, Byron P, McCann P, Maher L,. "Fitness for duty": social, organisational and structural influences on the design and conduct of candidate hepatitis C vaccine trials involving people who inject drugs. Vaccine 2010; 28 (32): 5228-5236.
29. Carrier N, Laplante J, Bruneau J,. Exploring the contingent reality of biomedicine: injecting drug users, hepatitis C virus and risk. Health, Risk Soc 2005; 7 (2): 123-140. (Pubitemid 40796998)
30. Munoz-Plaza C, Strauss S, Astone-Twerell J, et al,. Exploring drug users' attitudes and decisions regarding hepatitis C (HCV) treatment in the U.S. Int J Drug Policy 2008; 19 (1): 71-78. (Pubitemid 351200021)
31. Petraglia J,. The importance of being authentic: persuasion, narration and dialogue in health communication and education. Health Commun 2009; 24 (2): 176-185.
32. Noar SM, Benac CN, Harris MS,. Does tailoring matter? Meta-analytic review of tailored print health behavior change interventions. Psychol Bull 2007; 133 (4): 673-693.
33. Swan T,. The Hepatitis C Treatment Pipeline Report. New York: Treatment Action Group, 2011.
34. Sylvestre D, Zweben J,. Integrating HCV services for drug users: a model to improve engagement and outcomes. Int J Drug Policy 2007; 18 (5): 406-410. (Pubitemid 47381423)
35. Grebely J, Knight E, Genoway KA, et al,. Optimizing assessment and treatment for hepatitis C virus infection in illicit drug users: a novel model incorporating multidisciplinary care and peer support. Eur J Gastroenterol Hepatol 2010; 22 (3): 270-277.
36. Charlebois A, Lee L, Cooper E, Mason K, Powis J,. Factors associated with HCV antiviral treatment uptake among participants of a community-based HCV programme for marginalized patients. J Viral Hepat 2012; 19 (12): 836-842.
37. Stein M, Soloway I, Jefferson K, Roose R, Arnsten J, Litwin A,. Concurrent group treatment for hepatitis C: implementation and outcomes in a methadone maintenance treatment program. J Subst Abuse Treat 2012; 43 (4): 424-432.
38. O'Keefe D, Aitken C, Higgs P, Dietze P,. Concordance between self-reported and actual hepatitis C virus infection status in a cohort of people who inject drugs. Drug Alcohol Rev 2013; 32 (2): 208-210.
39. Geert Robaeys G, Grebely J, Mauss S, et al,. Recommendations for the management of hepatitis C virus infection among people who inject drugs. Clin Infect Dis 2013; 57 (Suppl. 2): S135-S143.
40. Foucher J, Reiller B, Jullien V, et al,. FibroScan used in street-based outreach for drug users is useful for hepatitis C virus screening and management: a prospective study. J Viral Hepat 2009; 16: 121-131.
41. Moessner B, Jørgensen T, Skamling M, et al,. Outreach screening of drug users for cirrhosis with transient elastography. Addiction 2011; 106: 970-976.